



## **XVI CONGRESSO NAZIONALE IG-IBD. Advances in IBD**

**Thursday, 27 November**

**14.00 – 14.30    Opening remarks**  
M.C. Fantini, IG-IBD  
*AMICI Onlus*

### **LECTURE**

Introduction:    Presentazione Fondazione IGIBD  
M.C. Fantini, S. Ardizzone

**14.30-15.00**    The scientific relevance of the ENEIDA registry  
Y. Zabana

### **SESSION I        ORAL COMMUNICATIONS**

Chairs: G. Maconi, A. Viola

- 15.00-15.10    **DEEP LEARNING FOR AUTOMATED AND OBJECTIVE IN VIVO ASSESSMENT OF INTESTINAL EPITHELIAL BARRIER INTEGRITY IN IBD USING PROBE-BASED CONFOCAL LASER ENDOMICROSCOPY**  
D. Noviello
- 15.10-15.20    **THE IUS-IBD SCORES CALCULATOR: AN IOS & ANDROID APP TO PROMOTE AND FACILITATE THE USE OF INTESTINAL ULTRASOUND SCORES IN IBD PATIENTS**  
F.M. Stalla
- 15.20-15.30    **INTESTINAL ULTRASOUND SCAN IN ACUTE SEVERE ULCERATIVE COLITIS IN CHILDREN: A MULTICENTER PROSPECTIVE STUDY ON BEHALF OF THE PORTO IBD WORKING GROUP OF ESPGHAN**  
L. Scarallo
- 15.30-15.40    **LEARNING CURVE IN INTESTINAL ULTRASOUND: ADVANCING FROM BASIC SKILLS TO ADVANCED COMPETENCIES — INSIGHTS FROM THE IUS IG-IBD MASTER PROGRAM**  
L. Bertin
- 15.40-15.50    **USE OF A MULTIMODAL LARGE LANGUAGE MODEL FOR THE AUTOMATIC SCORING OF THE MAYO ENDOSCOPIC SCORE IN COLONOSCOPY FRAMES OF ULCERATIVE COLITIS: A HUMAN-BLINDED DIAGNOSTIC ACCURACY STUDY OF GENERATIVE ARTIFICIAL INTELLIGENCE**  
A.G. Gravina
- 15.50-16.00    **PREDICTORS OF SUBOPTIMAL BOWEL PREPARATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDERGOING COLONOSCOPY: PRELIMINARY RESULTS FROM THE MULTICENTRIC IBD-WIN COLON STUDY**  
R. Pellegrino
- 16.00-16.30    Coffee break

## **SESSION II     Multidisciplinary thinking of Acute Severe Ulcerative Colitis**

**Chairs:** F. Rizzello, P. Sileri

- 17.45-18.05     Medical: getting started  
S. Festa
- 18.05-18.25     Medical: ready to rescue and maintain  
C. Bezzio
- 18.25-18.45     Surgical: ready to act  
M. Rottoli
- 18.45-19.00     Discussion

### **Friday, 28 November**

07.30-08.30     Early breakfast meetings

**Traveling with IBD, vaccination in IBD** | O.M. Nardone, M. Principi

**Taboo in IBD** | G. Privitera, A. Variola

### **LECTURE**

Introduction: M. Cappello

**08.30-09.00     Checkpoint inhibitor-induced colitis**  
M. Lenti

## **SESSION III     ORAL COMMUNICATIONS**

**Chairs:** P. Gionchetti, S. Renna

- 09.00-09.10     **SEQUENCING JAK-INHIBITORS IN ULCERATIVE COLITIS: EFFECTIVENESS AND SAFETY OF SWITCHING WITHIN TREATMENT CLASS**  
T. Innocenti
- 09.10-09.20     **REAL-WORLD EFFECTIVENESS AND SAFETY OF RISANKIZUMAB IN CROHN'S DISEASE: A SINGLE-CENTER EXPERIENCE**  
L. Centanni
- 09.20-09.30     **REAL-WORLD EFFECTIVENESS AND SAFETY OF MIRIKIZUMAB IN ULCERATIVE COLITIS PATIENTS**  
L. Melotti
- 09.30-09.40     **SWITCHING TO SUBCUTANEOUS ADMINISTRATION MAY OFFER MORE PROFOUND REMISSION COMPARED TO INTENSIFIED INTRAVENOUS THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND PARTIAL RESPONSE FOLLOWING INDUCTION WITH INTRAVENOUS VEDOLIZUMAB: THE PRIVEDO STUDY**  
F.S. Macaluso
- 09.40-09.50     **TREAT-TO-TARGET OPTIMIZATION IS EFFECTIVE ON ENDOSCOPIC AND HISTOLOGIC OUTCOMES IN A REAL-LIFE COHORT OF ULCERATIVE COLITIS – THE TACTIC-UC STUDY**  
G. Privitera
- 09.50-10.00     **EFFECTIVENESS AND SAFETY OF RESCUE MEDICAL THERAPY FOR CHILDREN DEVELOPING ACUTE SEVERE COLITIS AFTER INFLIXIMAB FAILURE (RESCUC): A MULTI-CENTER RETROSPECTIVE STUDY BY THE PORTO GROUP.**  
G. D'Arcangelo
- 10.00 – 10.30     Coffee break

#### **SESSION IV IUS replacing endoscopy and MRE?**

Chairs: A. Buda, E. Calabrese

- 11.15 – 11.35 IUS: what I can report, what I can't?  
M. Allocca
- 11.35 – 11.55 Endoscopy: sense and non-sense of endoscopic scores  
M. Daperno
- 11.55 – 12.15 MRE: when is it necessary, when is not?  
F. Maccioni
- 12.15 – 12.45 Discussion
- 12.45 – 13.45 Light lunch

#### **SESSION V ORAL COMMUNICATIONS**

Chairs: F. Facciotti, F. Zingone

- 15.00-15.10 **SINGLE-CELL DISSECTION OF PERIPHERAL CD3<sup>+</sup> T CELL REPERTOIRE REMODELING INDUCED BY ADVANCED COMBINATION TREATMENT IN INFLAMMATORY BOWEL DISEASE**  
V. Solitano
- 15.10-15.20 **THE HNF4A-IMP3-IL23R AXIS DRIVES GUT INFLAMMATION AND ANTI-TNF RESISTANCE IN IBD**  
A. Iannucci
- 15.20-15.30 **THE IBD-ASSOCIATED L503F VARIANT OF ORGANIC CATION TRANSPORTER NOVEL (OCTN-)1 PREDICTS A BETTER RESPONSE TO ANTITNFALPHA IN PATIENTS WITH ULCERATIVE COLITIS: A SINGLE CENTER ANALYSIS**  
S. Parello
- 15.30-15.40 **MAPPING THE IL-33/ST2 AXIS IN IBD: SITE-SPECIFIC IMMUNE SIGNATURES IN CROHN'S DISEASE AND ULCERATIVE COLITIS**  
C. Pane
- 15.40-15.50 **A CHRONIC MODEL OF EXPERIMENTAL IBD REVEALS SARCOPENIA AND LONG-TERM MOTOR DYSFUNCTION**  
S. Troisi
- 15.50-16.00 **COMPARATIVE OUTCOMES OF ULCERATIVE COLITIS PATIENTS WITH MES 1 AND HISTOLOGIC ACTIVITY VERSUS MES 2**  
I. Faggiani
- 16.00 – 16.30 Coffee break

#### **SESSION VI IBD in the extremes**

Chairs: S. Onali, A. Orlando

- 16.30– 16.50 Upper GI Crohn's disease  
L. Bertani
- 16.50 – 17.10 Asymptomatic terminal ileitis  
A. Testa
- 17.10 – 17.30 IBD in the rectum  
D. Pugliese
- 17.30 – 17.50 Discussion

#### **LECTURE**

Introduction: V. Annese

- 17.50-18.20 Preclinical IBD: is it possible to predict disease onset?**  
J. Torres

**18.30 – 19.30 ASSEMBLEA ORDINARIA DEI SOCI IG-IBD – EXTRA ECM**

**Saturday, 29 November**

**SESSION VII ORAL COMMUNICATIONS**

Chairs: G. Bodini, G. Dragoni

- 08.30-08.40 **CROHN'S DISEASE EXCLUSION DIET (CDED) PLUS PARTIAL ENTERAL NUTRITION VERSUS ORAL STEROIDS FOR INDUCTION AND MAINTENANCE OF REMISSION IN ADULT CROHN'S DISEASE: A PROSPECTIVE CASE-CONTROL STUDY**  
D.G. Ribaldone
- 08.40-08.50 **EFFECTIVENESS AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A REAL-LIFE MULTICENTER STUDY**  
F. Fanizzi
- 08.50-09.00 **EFFECTIVENESS AND SAFETY OF RISANKIZUMAB IN CROHN'S DISEASE PATIENTS FROM A LARGE ITALIAN COHORT: RESULTS FROM THE RESOLVE IGIBD STUDY**  
F. Di Vincenzo
- 09.00-09.10 **BEYOND ENDOSCOPY: EVALUATING NON-INVASIVE TOOLS FOR MONITORING POSTOPERATIVE CROHN'S DISEASE RECURRENCE**  
L. Bertin
- 09.10-09.20 **IMPACT OF TYPE 2 DIABETES ON CLINICAL OUTCOMES AND ADVANCED THERAPY USE IN PATIENTS WITH CROHN'S DISEASE: A REAL-WORLD PROPENSITY SCORE-MATCHED ANALYSIS**  
S. Massironi
- 09.20-09.30 **COMPARATIVE EFFECTIVENESS AND SAFETY OF TOFACITINIB AND FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS: A PROPENSITY SCORE-WEIGHTED COHORT STUDY**  
F.S. Macaluso

**LECTURE**

Introduction: M. Vecchi

- 09.30 -10.00 IBD and the autoimmune liver**  
N. Cazzagon

10.00 – 10.30 Coffee break

**LECTURE**

Introduction: S. Danese

- 11.45-12.15 Evolution of clinical trials in IBD**  
V. Jairath

**SESSION VIII Advanced therapy in IBD: one size does not fit all (to each his own)**

Chairs: F.S. Macaluso, S. Saibeni

- 12.15 – 12.35 **There is no drug like the first**  
G. Fiorino
- 12.35 – 12.55 **To each his own: second choices in Crohn's disease**  
F.A. Caprioli
- 12.55 – 13.15 **To each his own: second choices in ulcerative colitis**  
E.V. Savarino
- 13.15 – 13.30 Discussion
- 13.30 – 13.40 **Conclusions**